Skip to main content Help with accessibility Skip to main navigation

Dapagliflozin

Green (Restricted)

Brand:

Forxiga®

Nice TA:

288

Commissioning responsibility:

CCG

PbR excluded:

No

BNF chapter:
Endocrine system

Background

Dapagliflozin in a dual therapy regimen in combination with metformin is recommended as an option for treating type 2 diabetes, only if:
  1. a sulfonylurea is contraindicated or not tolerated or
  2. the person is at significant risk of hypoglycaemia or its consequences.
Dapagliflozin in combination with insulin with or without other antidiabetic drugs is recommended as an option for treating type 2 diabetes.
The third recommendation, previously part of this guidance, has been updated and replaced by NICE’s technology appraisal guidance on dapagliflozin in triple therapy for treating type 2 diabetes (TA418)
The LSCMMG recommends dapagliflozin as a 1st line ““gliflozin””.

Recommendation

LSCMMG Recommendation:

Green (Restricted)

Reason for decision:

Suitable for initiation in primary care in line with restrictions

Supporting documents:

Decisions of Lancashire local decision making groups

Green
Green
Green
Green
Green
Green
Green
Green
What do the colours mean?

Last Updated: 01 - Dec - 2016